Biogen Idec Retrieves its Idiopathic Pulmonary Fibrosis Drug via US$562.5 M Stromedix Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 2 (Table of Contents)
Published: 27 Feb-2012
DOI: 10.3833/pdr.v2012.i2.1691 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Consistent with its strategy of strengthening its pipeline beyond multiple sclerosis, Biogen Idec has agreed to acquire Stromedix, a clinical-stage biotech focused on fibrosis and organ failure, in a deal worth up to US$562...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS